CLDN5 and cancer: In vitro, cANGPTL4 interacts with integrin α5β1, VE-cadherin, and claudin-5 to disrupt endothelial cells and thus to increase vascular permeability [43]: this could be how cancer cells expressing and secreting cANGPTL4 could disrupt and thus cross the blood-brain barrier.